Drug updated on 10/29/2024
Dosage Form | Capsule (oral; Tafamidis 61 mg) |
Drug Class | Transthyretin stabilizers |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Latest News
Summary
- This summary is based on the review of 13 systematic review(s)/meta-analysis(es). [1-13]
- Tafamidis significantly reduced cardiovascular mortality (OR 0.58; 95% CI: [0.41-0.83], P=0.003) and all-cause mortality (OR 0.45; 95% CI: [0.32-0.64], P≤0.00001) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), with notable effectiveness observed across various subgroups including age, weight, and bioavailable testosterone levels. However, mortality was statistically insignificant in patients with heart transplants and mechanical assist devices.
- The treatment showed stability in echocardiographic findings and cardiac biomarkers during the study, with no significant deterioration in left ventricular ejection fraction (LVEF) in wild-type ATTR patients after tafamidis treatment.
- Significant differences in outcomes were noted between wild-type and hereditary ATTR, with the Val30Met genotype demonstrating the lowest survival rates. The analysis indicated that patients with wild-type ATTR were older and predominantly male compared to those with hereditary ATTR.
- Tafamidis was generally well-tolerated, with primarily mild to moderate adverse events reported, and no significant differences in mortality or severe adverse events between treatment and placebo groups.
- Common adverse events associated with tafamidis included nausea, flushing, and headache; however, no significant safety concerns were noted specifically among different population types or subgroups.
- Inotersen was highlighted as having a potentially higher risk profile, with increased mortality and severe adverse events compared to placebo, resulting in more participants discontinuing treatment due to adverse events.
- The studies indicate a focus on specific population types such as cardiac amyloidosis patients (including those with hypertrophic cardiomyopathy, heart failure with preserved ejection fraction, and elderly patients with aortic stenosis) and TTR-related familial amyloid polyneuropathy (FAP) populations, with relevant subgroup findings showing no significant deterioration in LVEF in wild-type ATTR patients post-tafamidis treatment, and varying survival estimates and mortality among different genotypes in hereditary ATTR; additionally, wild-type ATTR patients were found to be older and predominantly male compared to those with hereditary ATTR.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Vyndamax (tafamidis) Prescribing Information. | 2023 | Pfizer Inc., New York, NY |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis. | 2020 | Circulation Journal |
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. | 2020 | Canadian Journal of Cardiology |
Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis. | 2020 | Canadian Cardiovascular Society |
Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. | 2020 | Circulation |